AMAL Therapeutics is pioneering a novel approach to cancer treatment through its proprietary KISIMA® immunization technology, which focuses on developing therapeutic vaccines. Unlike traditional vaccines that prevent infections, therapeutic vaccines aim to harness a patient's immune system to combat existing diseases, particularly cancer. KISIMA® is a self-adjuvanting protein-based platform that delivers multiple antigens within a single vaccine, enhancing the immune response against tumor cells. This technology is designed to stimulate a robust cellular immune response, activating both CD8+ cytotoxic T lymphocytes and CD4+ helper T cells, which are crucial for recognizing and destroying cancer cells.

The company is particularly focused on creating effective cancer therapies, with its leading candidate being ATP128, aimed at treating metastatic colorectal cancer. AMAL Therapeutics seeks to address the limitations of current therapeutic vaccines, which often exhibit low efficacy and require complex preparation. By combining KISIMA® with immune-modulators, AMAL aims to improve the strength and duration of the immune response, thereby offering a new class of standardized therapeutic vaccines that can be administered more easily and affordably to a broader patient population. This innovative approach positions AMAL at the forefront of cancer immunotherapy, aiming to complement existing treatment modalities and enhance patient outcomes.

Switzerland

AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way. KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine. We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.

AMAL Therapeutics

Company Details